Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. It focuses on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases. Its lead product candidate is Lanifibranor that is Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The Company also develops Odiparcil, which is Phase IIa clinical trial for the treatment of mucopolysaccharidosis I, II and VI diseases; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment.